ZDHHC2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25793	1.00	3/20
SCHEMBL36870	1.00	3/20
SCHEMBL220516	1.00	3/20
SCHEMBL232770	1.00	3/20
SCHEMBL252114	1.00	3/20
SCHEMBL346798	1.00	3/20
SCHEMBL379942	1.00	3/20
SCHEMBL85840	0.44	3/20
SCHEMBL137967	0.72	2/20
SCHEMBL252541	0.72	2/20
SCHEMBL372568	0.72	2/20
SCHEMBL372601	0.72	2/20
SCHEMBL372802	0.72	2/20
SCHEMBL345353	0.61	2/20
SCHEMBL301435	0.57	2/20
SCHEMBL372729	0.57	2/20
SCHEMBL36287	0.50	2/20
SCHEMBL138376	0.50	2/20
Acrylic Acid (SCHEMBL57985)	0.44	2/20
Acrylic Acid (SCHEMBL160398)	0.44	2/20

Clinical trials — most relevant to ZDHHC2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver	PHASE2	COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease	nan	NOT_YET_RECRUITING
Gene Expression in Obesity and Insulin Resistance	nan	COMPLETED
for Adipose Tissue DIabetes VAriants (fATDIVA)	nan	COMPLETED
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Long Term Prediction of MASH-related HCC Risk by Proteomics	nan	NOT_YET_RECRUITING
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Genomic Dissection of a QTL Affecting the Lipid Profile	nan	WITHDRAWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Genetic Origin of Lipid Disorders	nan	UNKNOWN
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Acute Fatty Acid Intervention Study (AFAST)	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Gene Expression and Inflammation in Overweight Subjects	nan	COMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Epidemiology of Atherosclerosis	nan	COMPLETED
Genes Involved in Lipid Disorders	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women	nan	UNKNOWN
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ZDHHC2 binder may also engage these)

Protein	Name	Similarity
P59267	—	1.000	P59267 →
Q9JKR5	—	1.000	Q9JKR5 →
P0C7U3	—	0.997	P0C7U3 →
Q96MV8	—	0.997	Q96MV8 →
Q8WVZ1	—	0.996	Q8WVZ1 →
E9QCD3	—	0.996	E9QCD3 →
Q5BLG4	—	0.995	Q5BLG4 →
Q76IC6	—	0.994	Q76IC6 →
Q8IYP9	—	0.994	Q8IYP9 →
Q14AK4	—	0.994	Q14AK4 →
Q9NUE0	—	0.993	Q9NUE0 →
Q9H8X9	—	0.993	Q9H8X9 →
E7F587	—	0.993	E7F587 →
Q5R5J8	—	0.993	Q5R5J8 →
Q0VC89	—	0.993	Q0VC89 →
Q9NPG8	—	0.993	Q9NPG8 →
ZDHHC20	Palmitoyltransferase ZDHHC20	0.992	landscape →
Q5FWL7	—	0.992	Q5FWL7 →
F1QAM1	—	0.992	F1QAM1 →
F1RE57	—	0.992	F1RE57 →
A0A0R4IF99	—	0.991	A0A0R4IF99 →
Q2TGJ1	—	0.991	Q2TGJ1 →
Q8IZN3	—	0.991	Q8IZN3 →
Q5Y5T2	—	0.991	Q5Y5T2 →
Q5RB84	—	0.991	Q5RB84 →
Q6CUB5	—	0.991	Q6CUB5 →
F1QHM7	—	0.991	F1QHM7 →
Q6DHI1	—	0.990	Q6DHI1 →
Q8VYP5	—	0.990	Q8VYP5 →
F1QX91	—	0.990	F1QX91 →